Takeda Pharmaceutical (NYSE:TAK) Announces Earnings Results

Takeda Pharmaceutical (NYSE:TAK) issued its earnings results on Thursday, July 30th. The company reported $0.95 EPS for the quarter, topping the consensus estimate of $0.41 by $0.54, reports. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The company had revenue of $7.50 billion for the quarter, compared to analyst estimates of $7.13 billion. Takeda Pharmaceutical updated its FY 2026 guidance to 3.009-3.009 EPS.

Here are the key takeaways from Takeda Pharmaceutical’s conference call:

• Q1 results were broadly on plan: Core revenue declined 0.5% and core operating profit fell 0.5% at constant exchange rates, while core EPS decreased 11.8% to JPY 154 due largely to an unfavorable comparison with the prior year’s tax benefit. Full-year guidance, including JPY 650–750 billion of free cash flow, was maintained.
• The company reported continued resilience in its established portfolio, with core inline brands growing 2.3% at constant exchange rates. ENTYVIO grew 4%, new launches increased 22.6%, and transformation savings are intended to fund investments in upcoming products and the late-stage pipeline.
• Takeda is preparing for a potentially significant launch cycle, with ORZEYFUL for narcolepsy type 1 and rusfertide for polycythemia vera expected to launch in the U.S. in the second half of 2026, followed by zasocitinib for psoriasis in the first half of 2027. ORZEYFUL has already received its first approval in China, while rusfertide has received FDA priority review.
• Zasocitinib produced encouraging phase III psoriasis results, demonstrating statistical superiority to deucravacitinib across primary and key secondary endpoints, with more than 35% of patients achieving complete skin clearance at week 16. Management also highlighted promising data in difficult-to-treat areas and additional development opportunities in inflammatory bowel disease and other immune-mediated conditions.
• Near-term financial performance remains pressured by mature-product erosion, including continued generic competition for Vyvanse, while operating cash flow was lower because of working-capital effects and free cash flow included a $200 million payment to Protagonist related to rusfertide rights. ENTYVIO biosimilar litigation is expected to take roughly three to five years, with U.S. entry timing still broadly anticipated around 2032.

Takeda Pharmaceutical Trading Up 0.1%

NYSE:TAK traded up $0.01 during trading hours on Friday, reaching $18.04. 1,470,741 shares of the company were exchanged, compared to its average volume of 3,120,440. Takeda Pharmaceutical has a 52-week low of $12.99 and a 52-week high of $18.90. The firm has a market cap of $57.80 billion, a price-to-earnings ratio of 53.06 and a beta of -0.08. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. The stock has a 50 day simple moving average of $17.00 and a 200 day simple moving average of $17.20.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on TAK shares. Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Takeda Pharmaceutical presently has an average rating of “Hold”.

Insider Buying and Selling

In other news, insider Giles Richard Platford sold 31,083 shares of Takeda Pharmaceutical stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $531,519.30. Following the transaction, the insider directly owned 315,838 shares of the company’s stock, valued at $5,400,829.80. The trade was a 8.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Natalie Anne Marie Furney sold 30,868 shares of Takeda Pharmaceutical stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $17.10, for a total transaction of $527,842.80. Following the transaction, the general counsel directly owned 204,298 shares in the company, valued at approximately $3,493,495.80. This trade represents a 13.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 476,731 shares of company stock worth $8,192,525. Corporate insiders own 0.04% of the company’s stock.

Institutional Investors Weigh In On Takeda Pharmaceutical

A number of large investors have recently added to or reduced their stakes in the company. Sivia Capital Partners LLC purchased a new stake in shares of Takeda Pharmaceutical during the second quarter worth about $351,000. Kotler Kevin acquired a new position in Takeda Pharmaceutical during the 4th quarter worth $312,000. Franklin Resources Inc. grew its holdings in Takeda Pharmaceutical by 3.8% during the 3rd quarter. Franklin Resources Inc. now owns 19,458 shares of the company’s stock worth $285,000 after acquiring an additional 713 shares in the last quarter. Dorsey & Whitney Trust CO LLC increased its position in shares of Takeda Pharmaceutical by 14.0% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 17,584 shares of the company’s stock worth $274,000 after purchasing an additional 2,153 shares during the last quarter. Finally, Focused Alpha LLC acquired a new stake in shares of Takeda Pharmaceutical in the 4th quarter valued at about $221,000. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.